From: Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience
Characteristics | Nā=ā36 |
---|---|
Age, year | 75.5āĀ±ā5.4 |
Gender | |
Ā Male/female | 29/7 |
Body mass indexa, kg/m2 | 18.5āĀ±ā4.1 |
Preadmission of PFT | |
Ā FVCb, L | 1.6āĀ±ā0.6 |
Ā FVCb, % predicted | 55.8āĀ±ā16.5 |
Ā FEV1b, L | 1.5āĀ±ā0.5 |
Ā FEV1b, % predicted | 66.2āĀ±ā18.4 |
Ā FEV1/FVCb, % | 91.7āĀ±ā10.6 |
Ā DLcoc, mL/min/mmHg | 8.3āĀ±ā2.2 |
Ā DLcoc, % predicted | 62.4āĀ±ā14.9 |
Smoking status | |
Ā Current/former/never | 1/25/10 |
Treatment for IPF at baseline | |
Ā Pirfenidone | 4 |
Ā Nintedanib | 3 |
Ā Corticosteroid | 7 |
Ā Cyclosporine | 4 |
Ā None | 22 |
Long-term oxygen therapy | |
Ā Yes/no | 9/27 |